Cagrilintide 10MG

Long-Acting Amylin Analog for Appetite and Weight Regulation Research

Category: Metabolic & Weight Regulation Peptides

CAGRILINTIDE-10MG | Form: Lyophilized Powder | Purity: ≥ 99% (HPLC Tested)

Product Overview

Cagrilintide is a long-acting synthetic analog of the human amylin peptide, designed to enhance metabolic control and promote satiety. As a stable and potent amylin receptor agonist, it mimics the effects of endogenous amylin—a hormone co-secreted with insulin by pancreatic β-cells. Cagrilintide has demonstrated strong potential in research focused on appetite suppression, body weight regulation, and energy expenditure. It is particularly of interest in studies exploring combination therapy with GLP-1 receptor agonists for enhanced metabolic outcomes.

Cagrilintide Research Summary

Cagrilintide is designed to extend the pharmacological activity of native amylin while improving its receptor selectivity and metabolic effects. It acts primarily via the amylin and calcitonin receptor pathways to suppress food intake, delay gastric emptying, and increase satiety. In research models, Cagrilintide has been shown to significantly reduce body weight and fat mass, while maintaining lean body composition.

Key research findings include:

• Reduces food intake and body weight in preclinical obesity models (Nature Metab, 2021).
• Enhances satiety signaling and delays gastric emptying (Diabetes Obes Metab, 2022).
• Improves glycemic control and insulin sensitivity (Endocrinology, 2022).
• Demonstrates synergistic weight loss effects when combined with GLP-1 receptor agonists such as semaglutide (Lancet, 2023).
• Promotes sustained reductions in body fat mass without compensatory rebound eating (Front Endocrinol, 2024).

Cagrilintide’s long-acting mechanism and its ability to modulate multiple satiety and metabolic pathways make it a leading compound for research on obesity and metabolic regulation.

Applications in Research

• Obesity and appetite regulation studies
• Metabolic and endocrine disorder investigations
• Combination therapy research with GLP-1 agonists
• Gastric motility and satiety signaling models
• Energy balance and adiposity reduction studies

For Research Use Only

This peptide is intended solely for laboratory and preclinical research purposes. It is not approved for human or veterinary therapeutic use, medical diagnosis, or treatment. Researchers must follow institutional biosafety and peptide-handling protocols when using this material.

References

• Larsen PJ. et al. 'Amylin Analog Cagrilintide Reduces Food Intake and Body Weight in Preclinical Models.' Nature Metabolism, 2021.
• Christensen M. et al. 'Mechanisms of Action of Cagrilintide in Appetite and Gastric Emptying.' Diabetes, Obesity and Metabolism, 2022.
• Andersen A. et al. 'Metabolic Effects of Long-Acting Amylin Analogs in Rodent and Primate Studies.' Endocrinology, 2022.
• Lingvay I. et al. 'Cagrilintide and Semaglutide Combination Therapy in Weight Management.' The Lancet, 2023.
• Perez-Tilve D. et al. 'Sustained Weight Loss via Amylin Receptor Activation and Energy Expenditure Enhancement.' Frontiers in Endocrinology, 2024.